EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment

Minji Lee, Chi-Hwan Choi, Jin-Won Kim, Gyuri Sim, Sang Eun Lee, Hwachul Shin, Jeong Hyun Lee, Myung-Min Choi, Hwajung Yi, Yoon-Seok Chung iD

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Minji Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Cheongju, South Korea. Hauptthemen laut MEDLINE: Benzamides, Immunocompromised Host. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Disease Control and Prevention Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following the worldwide surge in mpox (monkeypox) in 2022, cases have persisted in Asia, including South Korea, and sexual contact is presumed as the predominant mode of transmission, with a discernible surge in prevalence among immunocompromised patients. Drugs such as tecovirimat can result in drug‐resistant mutations, presenting obstacles to treatment. This study aimed to ascertain the presence of tecovirimat‐related resistant mutations through genomic analysis of the monkeypox virus isolated from a reported case involving prolonged viral shedding in South Korea. Here, tecovirimat‐resistant mutations, previously identified in the B.1 clade, were observed in the B.1.3 clade, predominant in South Korea. These mutations exhibited diverse patterns across different samples from the same patient and reflected the varied distribution of viral subpopulations in different anatomical regions. The A290V and A288P mutant strains we isolated hold promise for elucidating these mechanisms, enabling a comprehensive analysis of viral pathogenesis, replication strategies, and host interactions. Our findings imply that acquired drug‐resistant mutations, may present a challenge to individual patient treatment. Moreover, they have the potential to give rise to transmitted drug‐resistant mutations, thereby imposing a burden on the public health system. Consequently, the meticulous genomic surveillance among immunocompromised patients, conducted in this research, assumes paramount importance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesImmunocompromised HostHumansVirus SheddingIsoindolesMutationRepublic of KoreaMpox, Monkeypox

Stichwörter der Autor:innen

Tecovirimatdrug resistancegenomic analysisimmunocompromised patientmonkeypox virusmpox

Substanzen

BenzamidesIsoindoles

Autor:innen und Institutionen

  • Division of High-risk Pathogens, Bureau of Infectious Disease Diagnosis Control, Korea Disease Control and Prevention Agency, Cheongju, South Korea.

ORCID-Profile: Yoon-Seok Chung

Förderung

  • Korea Disease Control and Prevention Agency

Zitieren

APA

Lee, M., Choi, C. H., Kim, J. W., Sim, G., Lee, S. E., Shin, H., Lee, J. H., Choi, M. M., Yi, H., & Chung, Y. S. (2024). Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment. Journal of Medical Virology. https://doi.org/10.1002/jmv.29536

Vancouver

Lee M, Choi CH, Kim JW, Sim G, Lee SE, Shin H, et al. Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment. Journal of Medical Virology. 2024. doi:10.1002/jmv.29536

BibTeX
@article{Lee2024,
  author = {Lee, Minji and Choi, Chi-Hwan and Kim, Jin-Won and Sim, Gyuri and Lee, Sang Eun and Shin, Hwachul and Lee, Jeong Hyun and Choi, Myung-Min and Yi, Hwajung and Chung, Yoon-Seok},
  title = {Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub‐lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29536}
}
Kostenlos starten →